Clinical Trial Update: Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation [Phase 1]

View source ↗

Summary

A Phase 1 study of Decitabine combined with a vaccine therapy for relapsed acute myeloid leukemia after allogeneic stem cell transplantation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Decitabine (Decitabine)
• Vaccine therapy

Snippet

Sponsor: University of Louisville | Conditions: Acute Myelogenous Leukemia | Phase 1 | Status: WITHDRAWN